Wroclaw-based Bioceltix debuts on the WSE main market

Bioceltix is working on three major projects with global potential – two drug candidates for dogs – for osteoarthritis and atopic dermatitis, and one drug candidate for horses suffering from arthritis.

“We have been consistently pursuing our growth strategy, the move to a major stock exchange is part of it. We announced it when we debuted on NewConnect, and now we are simply fulfilling those promises.”
 – says PhD, Eng. Paweł Wielgus, board member of Bioceltix.

On the other hand, Lukasz Bzdzion, president and co-founder of the Wroclaw-based company, notes the advancement of ongoing projects.

“We are pleased that the stock market plans go hand in hand with the advancement of projects. We are maintaining a good pace in all areas. As planned and announced, we are in the right research phase in a clinical pilot for atopic dermatitis and a clinical trial for osteoarthritic lesions in dogs, as well as a safety study in horses. This means that in all projects we are already after administering our drug candidates to animals.”
– adds Łukasz Bzdzion.

The company has just completed a marketing campaign aimed at recruiting patients for a clinical pilot for atopic dermatitis in dogs, conducted jointly with the Wroclaw University of Life Sciences. As the company assures, thanks to a well-targeted marketing effort, it was possible to reach brand new caregivers of dogs suffering from AD, hence the recruitment, and hence the study itself, is going at a good pace.

“We already have the first patient who has completed the study in full, i.e. he is after 90 days of observation, while it is still too early to draw far-reaching conclusions.”
– emphasizes Łukasz Bzdzion.

In the context of progress on the drug for canine arthritis, patient recruitment is also on schedule. In the case of horses, the safety study should be completed in November, which is much easier to plan for since Bioceltix is not doing dedicated recruitment in this study, but is working with previously enrolled and identified animals.

“We are growing at the pace we promised our shareholders. This allows us – despite the currently difficult external environment – to look to the future with optimism. We expect to have some really interesting discussions with industry partners in late autumn or early winter, following further results.”
– concludes PhD Eng. Paweł Wielgus.

If all goes according to plan, Bioceltix will launch its first drug with global potential – for arthritis in dogs – as early as 2024.

Bioceltix’s stock price seems to be immune to the bear offensive so far, as it has risen more than 50% since the bottom established at the end of July.

Bioceltix is a biotechnology company developing advanced medicinal products for companion animals with a focus on dogs and horses. The company is developing proprietary technology to produce biological drugs based on mesenchymal stem cells. The breakthrough of Bioceltix’s approach is the use of a method that allows stem cells from a small number of healthy donors to be administered to a large number of patients, an allogeneic model. The therapeutic products developed in this way will be available off-the-shelf, on-site at the veterinary clinic and ready for administration to the patient immediately after thawing. The biologic drugs being developed at Bioceltix have the potential – in addition to having a symptomatic effect – to exhibit a causal effect by influencing the inflammatory environment and activating the natural mechanisms of restoration of affected tissues.